IL165860A0 - Administration of therapeutic viruses - Google Patents
Administration of therapeutic virusesInfo
- Publication number
- IL165860A0 IL165860A0 IL16586004A IL16586004A IL165860A0 IL 165860 A0 IL165860 A0 IL 165860A0 IL 16586004 A IL16586004 A IL 16586004A IL 16586004 A IL16586004 A IL 16586004A IL 165860 A0 IL165860 A0 IL 165860A0
- Authority
- IL
- Israel
- Prior art keywords
- administration
- therapeutic viruses
- viruses
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39063202P | 2002-06-21 | 2002-06-21 | |
PCT/US2003/016474 WO2004000209A2 (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
IL165860A0 true IL165860A0 (en) | 2006-01-15 |
Family
ID=30000590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16586004A IL165860A0 (en) | 2002-06-21 | 2004-12-19 | Administration of therapeutic viruses |
Country Status (11)
Country | Link |
---|---|
US (2) | US20050220818A1 (xx) |
EP (2) | EP2266601A1 (xx) |
JP (1) | JP2006511450A (xx) |
AU (1) | AU2003243307B2 (xx) |
CA (1) | CA2489523A1 (xx) |
IL (1) | IL165860A0 (xx) |
MX (1) | MXPA04012881A (xx) |
NZ (1) | NZ537255A (xx) |
RU (1) | RU2314830C2 (xx) |
WO (1) | WO2004000209A2 (xx) |
ZA (1) | ZA200410229B (xx) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2408387C2 (ru) | 2004-04-27 | 2011-01-10 | Веллстат Байолоджикс Корпорейшн | Лечение злокачественного новообразования с применением вирусов и камптотецинов |
EP1907015B1 (en) | 2005-07-14 | 2012-01-11 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
ES2380289T3 (es) | 2009-11-30 | 2012-05-10 | United Cancer Research Institute | Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer |
US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
US20140087362A1 (en) | 2012-03-16 | 2014-03-27 | Aladar A. Szalay | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
DK3207130T3 (da) | 2014-10-14 | 2019-11-11 | Halozyme Inc | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme |
KR102536850B1 (ko) | 2016-04-15 | 2023-05-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
JP7527758B2 (ja) | 2016-04-15 | 2024-08-05 | アルパイン イミューン サイエンシズ インコーポレイテッド | Cd80バリアント免疫調節タンパク質およびその使用 |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
JP2020500010A (ja) | 2016-10-20 | 2020-01-09 | アルパイン イミューン サイエンシズ インコーポレイテッド | 分泌性バリアント免疫調節タンパク質および改変細胞療法 |
US11920156B2 (en) | 2017-02-09 | 2024-03-05 | Indapta Therapeutics, Inc. | Engineered natural killer (NK) cells and compositions and methods thereof |
EP4306537A3 (en) | 2017-03-16 | 2024-03-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
US11732022B2 (en) | 2017-03-16 | 2023-08-22 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
WO2019079520A2 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF |
WO2019236633A2 (en) | 2018-06-04 | 2019-12-12 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
JP7329593B2 (ja) | 2018-11-06 | 2023-08-18 | カリディ・バイオセラピューティクス・インコーポレイテッド | 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系 |
JP7541516B2 (ja) | 2018-11-21 | 2024-08-28 | インダプタ セラピューティクス インコーポレイテッド | ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 |
CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
SG11202108459QA (en) | 2019-02-27 | 2021-09-29 | Actym Therapeutics Inc | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
KR20230088306A (ko) | 2020-04-22 | 2023-06-19 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해(nk) 세포 조성물 및 이를 생성하는 방법 |
WO2021258008A1 (en) * | 2020-06-19 | 2021-12-23 | Immunacor Llc | Compositions and methods for treating and preventing viral infection |
WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
ATE236271T1 (de) * | 1993-04-30 | 2003-04-15 | Wellstat Biologics Corp | Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung |
EP0848956A1 (en) * | 1996-12-17 | 1998-06-24 | Dimminaco Ag/Sa/Ltd. | In ovo vaccination against Newcastle Disease |
HUP0003911A3 (en) * | 1997-10-09 | 2007-11-28 | Pro Virus | Treatment of neoplasms with viruses |
US7470426B1 (en) * | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
MXPA01010393A (es) * | 1999-04-15 | 2004-04-02 | Pro Virus Inc | Tratamiento de neoplasmas con virus. |
US20050074901A1 (en) * | 2002-02-13 | 2005-04-07 | John Castracane | Methods and assays for detecting and quantifying the human p53 inducible gene protein |
JP2006510741A (ja) * | 2002-11-05 | 2006-03-30 | ウェルスタット バイオロジックス コーポレイション | 治療用ウイルスによるカルチノイド新生物の処置 |
-
2003
- 2003-05-22 US US10/518,732 patent/US20050220818A1/en not_active Abandoned
- 2003-05-22 JP JP2004515715A patent/JP2006511450A/ja not_active Ceased
- 2003-05-22 RU RU2005101351/14A patent/RU2314830C2/ru not_active IP Right Cessation
- 2003-05-22 NZ NZ537255A patent/NZ537255A/en not_active IP Right Cessation
- 2003-05-22 CA CA002489523A patent/CA2489523A1/en not_active Abandoned
- 2003-05-22 MX MXPA04012881A patent/MXPA04012881A/es active IP Right Grant
- 2003-05-22 EP EP10179896A patent/EP2266601A1/en not_active Withdrawn
- 2003-05-22 AU AU2003243307A patent/AU2003243307B2/en not_active Ceased
- 2003-05-22 EP EP03761032A patent/EP1539230A4/en not_active Withdrawn
- 2003-05-22 WO PCT/US2003/016474 patent/WO2004000209A2/en active Search and Examination
-
2004
- 2004-12-19 IL IL16586004A patent/IL165860A0/xx unknown
- 2004-12-20 ZA ZA200410229A patent/ZA200410229B/xx unknown
-
2009
- 2009-03-24 US US12/409,711 patent/US20090180993A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004000209A3 (en) | 2005-03-03 |
NZ537255A (en) | 2009-04-30 |
RU2005101351A (ru) | 2005-08-10 |
AU2003243307B2 (en) | 2010-04-01 |
EP1539230A4 (en) | 2007-10-31 |
JP2006511450A (ja) | 2006-04-06 |
EP1539230A2 (en) | 2005-06-15 |
WO2004000209A2 (en) | 2003-12-31 |
ZA200410229B (en) | 2006-07-26 |
US20050220818A1 (en) | 2005-10-06 |
AU2003243307A1 (en) | 2004-01-06 |
CA2489523A1 (en) | 2003-12-31 |
US20090180993A1 (en) | 2009-07-16 |
EP2266601A1 (en) | 2010-12-29 |
RU2314830C2 (ru) | 2008-01-20 |
MXPA04012881A (es) | 2005-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200410229B (en) | Administration of therapeutic viruses | |
GB0201850D0 (en) | Therapeutic treatment | |
GB0216321D0 (en) | Therapeutic treatment | |
IL169338A0 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
HK1073997A1 (en) | Administration of agents for the treatment of inflammation | |
AU2003224725A8 (en) | Hiv therapeutic | |
IL172733A0 (en) | Diphenylpyridine derivatives, preparation and therapeutic application thereof | |
ZA200707934B (en) | Thereapeutic formulations for the treatment of beta-amyloid related diseases | |
HK1095036A1 (en) | Virus therapeutic drug | |
EP1487411A4 (en) | THERAPEUTIC FORMULATIONS SUPPORTED BREATHABLE | |
HK1078784A1 (en) | Therapeutic treatment | |
IL166337A0 (en) | Oral administration of calctionin | |
AU2003279911A8 (en) | Therapeutic formulations | |
TWI319400B (en) | Piperazinylacylpiperidine derivatives, their preparation and their therapeutic application | |
AU2003294318A8 (en) | Therapeutic bioconjugates | |
GB0223367D0 (en) | Therapeutic treatment | |
PT1525193E (pt) | Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide | |
GB0202900D0 (en) | Novel formulations of drugs | |
HK1074444A1 (en) | Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof | |
EP1670755A4 (en) | PYROVALERON ANALOGUE AND ITS THERAPEUTIC APPLICATIONS | |
GB0210464D0 (en) | Therapeutic treatment | |
IL165612A0 (en) | Novel arylimidazole derivatives preparation and therapeutic uses thereof | |
GB0210741D0 (en) | Methods of therapy | |
AU2003296385A8 (en) | Therapeutic single dose gas administration system | |
EP1485077A4 (en) | DRUGS COMBINATION THERAPY |